Low dose Canagliflozin effectively reduces hs-CRP and CR markers in diabetes

Delhi: Canagliflozin 100mg is as good as canagliflozin 300mg in the reduction of hs-CRP and CR markers in patients with type 2 diabetes, according to a recent study. The findings of the study were presented at the American Diabetes Association (ADA) 80th Scientific Sessions held from June 12-16, 2020, and subsequently published in the journal Diabetes.

Canagliflozin (Invokana) is a third-line medication to metformin used for the treatment of type 2 diabetes. It reduces the blood sugar levels by helping the kidneys get rid of glucose from the bloodstream. Invokana is supplied as film-coated tablets for oral administration, containing 100 mg and 300 mg of canagliflozin (anhydrous) in each tablet. 

Vishal Gupta from Mumbai, India, and colleagues compared the efficiency of both different doses of Canagliflozin (C1) 100mg & Canagliflozin (C3) 300mg on highly reactive sensitive C reactive protein (hs-CRP) and other cardio-renal (CR) biomarkers. 

For the study, the researches identified a cohort of 190 patients with type 2 diabetes mellitus (T2DM) aged 18-75 years, irrespective of baseline A1c, receiving SGLTi C1 or C3. They performed a propensity score 1:1 matching for both the groups with variables that could affect treatment outcomes and minimize confounding. The patients were evaluated every 2-3months for CR biomarkers (body mass index (BMI), A1c, systolic (S) BP, diastolic (D) BP, Lipid profile (TC, LDL, TG, HDL), Hs-CRP, creatinine, eGFR, and urinary albumin/creatinine ratio {UACR}). NT-ProBNP was evaluated at 12 months. 44 patients were identified in the C1 group and 44 in the C3 group.' 

Key findings of the study include:

• Reduction in C1 group (baseline to 12m): there was a S reduction in hs-CRP, A1c, BMI, SBP, DBP, TC, TG, LDL.

• Reduction in C3 group (baseline to 12m): there was a S reduction in hs-CRP, A1c, BMI, SBP, DBP, TC, LDL.

• Difference between C1 and C3 at 12m: There was no difference in biomarkers between both the groups, included Lipid profile, SBP and DBP.

"Both Canagliflozin 100mg and Canagliflozin 300mg has similar efficiency for the reduction of hs-CRP and CR markers in type 2 diabetes patients," concluded the authors.

For further reference follow the link: https://doi.org/10.2337/db20-2219-PUB